SUMMARY

[0009] The anti-TSLP antibody described herein addresses an unmet need in patients with chronic rhinosinusitis, with or without nasal polyps, in which other medications may not control symptoms. For example, the antibody therapy may improve nasal polyp score, loss of smell, or reduce the need for surgery to remove polyps in patients with chronic rhinosinusitis, as well as reduce the need for alternate therapies such as systemic corticosteroids.

[0010] In one aspect, the present disclosure provides a use of an anti-TSLP antibody or antibody variant to the subject in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or B. a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0010a] The disclosure provides, in part, a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a therapeutically effective amount of an anti-TSLP antibody or antibody variant to the subject, wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0011] In another aspect, the present disclosure provides a use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the composition is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or B. a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0011a] Also provided is a method for treating chronic rhinosinusitis in a subject comprising administering a composition comprising an anti-TSLP antibody in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or wherein both binding sites of the antibody have identical binding to TSLP, and the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0012] In yet another aspect, the present disclosure provides a use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the composition comprising an anti-TSLP antibody is to be administered to the subject in a dose of 140 to 420 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein the antibody is an IgG2 antibody.

[0012a] The disclosure further provides a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid

sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0013] Also provided is a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 140 mg to 420 mg at an interval of every two weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0014] In various examples, the antibody is administered every 4 weeks. In various examples, the antibody is administered at a dose of 140 mg or at a dose of 420 mg every 2 weeks or every 4 weeks. In various examples, the antibody is administered at a dose of 140 mg or at a dose of 210 mg every 2 weeks or every 4 weeks.

[0015] In various examples, the antibody is administered at a dose of 210 mg every 2 weeks. In various examples, the antibody is administered at a dose of 210 mg every 4 weeks.

[0016] In various examples, the subject is also receiving treatment with corticosteroids.

[0017] In various examples, provided is a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a therapeutically effective amount of a systemic corticosteroid and a composition comprising an anti-TSLP antibody to the subject in a dose of 210 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set

forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0018] In various examples, provided is a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a therapeutically effective amount of a systemic corticosteroid and a composition comprising an anti-TSLP antibody to the subject in a dose of 210 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0019] The disclosure also provides a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein both the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0020] The disclosure further provides a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0021] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0022] In various examples, the anti-TSLP antibody or variant has substantially similar pK characteristics as tezepelumab in humans.

[0023] In various examples, the antibody or antibody variant is administered for a period of at least 4 months, 6 months, 9 months, 1 year or more.

[0024] In various examples, the anti-TSLP antibody or antibody variant thereof is bivalent and selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an antigen-binding antibody fragment, a single chain antibody, a monomeric antibody, a Fab fragment, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

[0025] In various examples, the anti-TSLP antibody thereof is bivalent and selected from the group consisting of a human antibody, a humanized antibody, a chimeric antibody, a monoclonal antibody, a recombinant antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

[0026] In one example, the anti-TSLP antibody variant is selected from the group consisting of a Fab fragment, a single domain antibody, an scFv, wherein the dose is adjusted such that the binding sites are equimolar to those dosed by bivalent antibodies.

[0027] In various examples, the antibody is an IgG2 antibody.

[0028] In one example, the antibody or antibody variant is a human or humanized antibody.

[0029] In various examples, the antibody is tezepelumab. In various examples, the anti-TSLP antibody is an IgG2 antibody having the full length heavy and light chain amino acid sequences set out in SEQ ID NOs: 13 and 14, respectively. In various examples, the anti-TSLP antibody is tezepelumab.

[0030] In various examples, the antibody or antibody variant further is in a pharmaceutical composition further comprising a pharmaceutically acceptable carrier or excipient.

[0031] In various examples, the antibody is an anti-TSLP antibody described in the art. Exemplary antibodies are described further in the Detailed Description.

[0032] In various examples, the subject is an adult. In various examples, the subject is a child or adolescent.

[0033] It is further provided that administration of the anti-TSLP antibody or antibody variant decreases levels of Th2 cytokines in the subject.

[0034] In various examples, administration of the anti-TSLP antibody or antibody variant improves one or more of the following measures of chronic rhinosinusitis: Nasal Polyp Score (NPS), Nasal Congestion Score (NCS), loss of smell, SinoNasal Outcome Test 22 Item (SNOT-22), EuroQOL quality of life 5-dimensions 3-level version (EQ-5D-3L), Asthma Control Questionnaire (ACQ-6), Lund-Mackay score, modified Lund-Mackay Score, incidence of nasal polyp surgery and/or systemic corticosteroids (SCS).

[0035] In various examples, the NPS and or the NCS is reduced by one, two or three points. In various examples, the subject has an NPS score of 0 (none) or 1 (mild) at week 52 after treatment. In various examples, the subject has a starting NPS score of 2. In various examples, the subject has a starting NPS score of 3. In various examples, the subject has an NCS score of 0 (none) or 1 (mild) at week 52 after treatment. In various examples, the subject has a starting NCS score of 2. In various examples, the subject has a starting NCS score of 3.

[0036] In various examples, treatment with anti-TSLP modulates the levels of one or more of the following biomarkers of chronic rhinosinusitis: cytokines, IgE, CCL17, CCL18, CCL22, and RNA transcriptional changes in nasal epithelium. In various examples, treatment with anti-TSLP reduces the level of Th2 cytokines. In various examples, the

treatment modulates (reduces or moderates) levels of or activity of one or more of IL-4, IL-5, IL-13, IL-17, IL-22, IL-23, IL-31, or combinations thereof.

[0037] In a further aspect, the present disclosure provides a use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for treating chronic rhinosinusitis with nasal polyps in a subject selected to be in need of treatment for chronic rhinosinusitis with nasal polyps, wherein the composition comprising an anti-TSLP antibody is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or B. wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b). Provided herein are methods for treating chronic rhinosinusitis with nasal polyps in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis with nasal polyps, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises

[0038] A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8; or,

[0039] B. a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0040] Further provided is a method for treating chronic rhinosinusitis in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 140 to 420 mg at an interval of every 2 or every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain

comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein the antibody is an IgG2 antibody.

[0041] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0042] In various examples, the antibody is administered every 4 weeks. In various examples, the antibody is administered at a dose of 210 mg every 2 weeks or every 4 weeks.

[0043] In various examples, the antibody is administered at a dose of 210 mg every 4 weeks.

[0044] Also provided is a method of reducing the frequency of surgery needed or systemic corticosteroids in a subject having chronic rhinosinusitis, with or without nasal polyps, comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising of an anti-TSLP antibody to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0045] Also provided is a method of reducing the frequency of surgery needed or systemic corticosteroids in a subject having chronic rhinosinusitis, with nasal polyps, comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising of an anti-TSLP antibody to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid

sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0046] In a further aspect, the present disclosure provides a use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for reducing the frequency of chronic rhinosinusitis exacerbation in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the composition comprising an anti-TSLP antibody is to be administered to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or B. a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0046a] Further provided is a method of reducing the frequency of chronic rhinosinusitis exacerbation in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0047] Also provided is a method of reducing the frequency of chronic rhinosinusitis exacerbation in a subject comprising selecting a subject in need of treatment for chronic rhinosinusitis, administering a composition comprising an anti-TSLP antibody to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent

conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0048] In a further aspect, the present disclosure provides a use of a composition comprising of an anti-TSLP antibody in the manufacture of a medicament for reducing SNOT-22 score, Lund-Mackay score, or both SNOT-22 and Lund-Mackay score in a subject, wherein the composition comprising of an anti-TSLP antibody is to be administered in a dose of 140 mg to 420 mg at an interval of every 2 weeks, wherein the antibody comprises A. a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or B. wherein the antibody comprises a. a light chain variable domain selected from the group consisting of i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0048a] In a further aspect, the present disclosure provides a use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for reducing SNOT-22 score, Lund-Mackay score, or both SNOT-22 and Lund-Mackay score in a subject, wherein the composition comprising an anti-TSLP antibody is to be administered in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises A. a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or B. wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0048b] Also provided are methods for reducing SNOT-22 and/or Lund-Mackay score in a subject comprising administering a composition comprising an anti-TSLP antibody in a dose of 140 mg to 420 mg at an interval of every 2 weeks, or at a dose of 210 mg at an interval or every 4 weeks, wherein the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0049] In various examples, the disclosure provides a method for reducing SNOT-22 and/or Lund-Mackay score in a subject comprising administering a composition comprising an anti-TSLP antibody in a dose of 140 mg to 420 mg at an interval of every 2 weeks, or at a dose of 210 mg at an interval or every 4 weeks, the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0050] In various examples, the disclosure provides a method for reducing a SNOT-22 domain score in a subject comprising administering a composition comprising an anti-TSLP antibody in a dose of 140 mg to 420 mg at an interval of every 2 weeks, or at a dose of 210 mg at an interval or every 4 weeks, wherein the antibody comprises a. a light chain variable domain comprising: i. a light chain CDR1 sequence comprising the amino acid sequence

set forth in SEQ ID NO:3; ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4; iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and b. a heavy chain variable domain comprising: i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6; ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

[0051] In various examples, the SNOT-22 domain is Nasal Domain, Ear/Facial Domain, Sleep Domain, Function Domain or Emotion Domain. In various examples, the administration ameliorates one or more symptoms of the domain score selected from: need to blow nose, nasal blockage, sneezing, runny nose, cough, post-nasal discharge, thick nasal discharge, decreased sense of smell/taste; ear fullness, dizziness, ear pain, facial pain/pressure; difficulty falling asleep, wake up at night, lack of a good night's sleep, wake up tired; fatigue, reduced productivity, reduced concentration, frustrated/restless/irritable, sadness, and embarrassment.

[0052] In various examples, the antibody comprises a. a light chain variable domain selected from the group consisting of: i. a sequence of amino acids at least 80% identical to SEQ ID NO:12; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and b. a heavy chain variable domain selected from the group consisting of: i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10; ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9; iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

[0053] In various examples, the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

[0054] In various examples, the antibody is tezepelumab.

[0055] It is provided that the dosing and antibody and antibody variant types referenced above apply to each method contemplated herein.

[0056] In various examples, provided is a pharmaceutical composition comprising an antibody or antibody variant and further comprising a pharmaceutically acceptable carrier or excipient.

[0057] In various examples, the administration delays the time to a chronic rhinosinusitis exacerbation compared to a subject not receiving the anti-TSLP antibody or a patient's baseline symptoms prior to receiving treatment with an anti-TSLP antibody or antibody variant. Examples of such an antibody include tezepelumab.

[0058] In various examples, the administration delays the incidence or time to nasal polyp surgery in a subject with chronic rhinosinusitis compared to a subject not receiving the anti-TSLP antibody.

[0059] Administration of just TSLP antibody or antibody variant can be done subcutaneously.

[0060] In various examples, the administration reduces frequency of or levels of co-administered therapy in the subject. Exemplary co-administered therapy is dupilumab, immunosuppressive or immunomodulating drugs (e.g., systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon (IFN)-gamma, Janus kinase inhibitors, azathioprine, methotrexate), anti-IL-13 antibodies, anti-IL-5 pathway antibodies (benralizumab, mepolizumab, reslizumab), or combinations thereof. "Co-administration" for this purpose would cover the administration of two different molecules sited above in the same syringe/autoinjector, or two different syringe/autoinjectors. The different molecules above can also be administered at the same time or at different times.

[0061] In various examples, the administration reduces or eliminates the need for corticosteroid therapy.

[0062] In various examples, the administration is subcutaneous or intravenous.

[0063] In a further aspect, the present disclosure provides a use of an anti-TSLP antibody or antibody variant in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the anti-TSLP antibody or antibody variant is to be administered to the subject, wherein the anti-TSLP antibody or antibody variant is described in WO 20220226342A1, WO 20220226339A1, WO2023098491A1, WO2021155634A1, WO2022166072A1, WO2021043221A1, WO2022184074A1, WO2021104053A1, WO2023116925A1, WO2021155861A1, WO2022116858A1, WO2022117079A1, WO2020244544A1, WO2021152488A1, WO2022253147A1, WO2023070948A1, WO2023142309A1, WO2022095689A1, WO2021115240A1, WO2022166739A1 and WO2019100111A1 or set out in Table A. In various examples, the antibody is tezepelumab or another anti-TSLP antibody or antibody variant described in the art, e.g., in Table A or in WO 20220226342A1, WO 20220226339A1, WO2023098491A1, WO2021155634A1, WO2022166072A1, WO2021043221A1, WO2022184074A1, WO2021104053A1, WO2023116925A1, WO2021155861A1, WO2022116858A1, WO2022117079A1, WO2020244544A1, WO2021152488A1, WO2022253147A1, WO2023070948A1, WO2023142309A1, WO2022095689A1, WO2021115240A1, WO2022166739A1 and WO2019100111A1. Exemplary antibodies are described further in the Detailed Description.

WHAT IS CLAIMED

1. Use of an anti-TSLP antibody or antibody variant to the subject in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the antibody comprises

A.

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or

B.

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

2. The use of claim 1, wherein the antibody is to be administered every 2 weeks or every 4 weeks.

3. The use of any one of claims 1 to 2, wherein the antibody is an IgG2 antibody.

4. The use of any one of claims 1 to 3, wherein the antibody is to be administered at a dose of between 140 and 420 mg, at a dose of 210 mg or at a dose of 420 mg.

5. Use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the composition is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises

A.

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or

B.

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b), wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2.

6. The use of any one of the preceding claims wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

7. The use of any one of the preceding claims, wherein i) the chronic rhinosinusitis is severe or moderate chronic rhinosinusitis; ii) the chronic rhinosinusitis is with nasal polyps; iii) the chronic rhinosinusitis is severe or moderate chronic rhinosinusitis and the chronic rhinosinusitis is with nasal polyps; or iv) the chronic rhinosinusitis is severe or moderate chronic rhinosinusitis and the chronic rhinosinusitis is with nasal polyps and the subject has moderate asthma.

8. The use of any one of the preceding claims, wherein the subject is an adult or wherein the subject is a child or adolescent.

9. The use of any one of the preceding claims,

i) wherein the administration improves one or more measures of chronic rhinosinusitis including Nasal Polyp Score (NSP), Nasal Congestion Score (NCS), loss of smell, SinoNasal Outcome Test 22 Item (SNOT-22), EuroQOL quality of life 5-dimensions 3-level version (EQ-5D-3L), Asthma Control Questionnaire (ACQ-6), Lund-Mackay score, modified Lund-Mackay Score, incidence of nasal polyp surgery; systemic corticosteroids (SCS) or combinations thereof;

ii) wherein the administration improves one or more measures of chronic rhinosinusitis as measured by a patient symptom diary; or

iii) wherein the administration improves one or more measures of chronic rhinosinusitis selected from the group consisting of nasal blockage, nasal congestion, runny nose, post-nasal drip, mucus drainage down the throat, prominent nasal obstruction, nasal discharge, loss of smell, asthma symptoms, headache, facial pain, facial pressure, difficulty with sense of smell, difficulty with sleeping due to nasal symptoms, difficulty with daily activities due to nasal symptoms.

10. Use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the composition comprising an anti-TSLP antibody is to be administered to the subject in a dose of 140 to 420 mg at an interval of every 2 weeks, wherein the antibody comprises

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antibody specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2, wherein the antibody is an IgG2 antibody.

11. The use of claim 10, wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

12. The use of claim 10 or 11, wherein the antibody is to be administered every 4 weeks.

13. The use of anyone of claims 10-12, wherein the antibody is to be administered at a dose of 210 mg, or at a dose of 420 mg.

14. The use of any one of the preceding claims, wherein the antibody is tezepelumab.

15. The use of claim 14, wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 13 and 14, respectively.

16. The use of any one of the preceding claims, wherein the antibody variant has similar pK characteristics as tezepelumab in humans.

17. Use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for reducing the frequency of chronic rhinosinusitis exacerbation in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the composition comprising an anti-TSLP antibody is to be administered to the subject in a dose of 140 mg to 420 mg at an interval of every 2 weeks or every 4 weeks, wherein the antibody comprises

A.

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or

B.

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

18. The use of claim 17, wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

19. The use of claim 17 or 18, wherein the antibody is to be administered every 4 weeks.

20. The use of any one of claims 17 to 19, wherein the antibody is to be administered at a dose of 210 mg or at a dose of 420 mg.

21. The use of any one of claims 17 to 20 wherein the antibody is tezepelumab.

22. The use of any one of claims 17 to 21, wherein i) the administration delays the time to a chronic rhinosinusitis exacerbation compared to a subject not receiving the anti-TSLP antibody; ii) reduces frequency of or levels of co-administered therapy in the subject; or iii) the administration delays the time to a chronic rhinosinusitis exacerbation compared to a subject not receiving the anti-TSLP antibody and reduces frequency of or levels of co-administered therapy in the subject;.

23. The use of claim 22, wherein the co-administered therapy is selected from the group consisting of dupilumab, immunosuppressive or immunomodulating drugs, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon (IFN)-gamma, Janus kinase inhibitors, azathioprine, methotrexate, anti-IL-13 antibodies, anti-IL-5 pathway antibodies, or combinations thereof.

24. The use of claim 23, wherein the administration reduces or eliminates the need for corticosteroid therapy.

25. Use of a composition comprising of an anti-TSLP antibody in the manufacture of a medicament for reducing SNOT-22 score, Lund-Mackay score, or both SNOT-22 and Lund-Mackay score in a subject, wherein the composition comprising of an anti-TSLP antibody is to be administered in a dose of 140 mg to 420 mg at an interval of every 2 weeks, wherein the antibody comprises

A.

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or

B.

wherein the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

26. Use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for reducing SNOT-22 score, Lund-Mackay score, or both SNOT-22 and Lund-Mackay score in a subject, wherein the composition comprising an anti-TSLP antibody is to be administered in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises

A.

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or

B.

wherein the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

27. The use of any one of claims 25 to 26 wherein the subject has a nasal polyp score (NPS) of 0 or 1 after 52 weeks of treatment.

28. The use of any one of claims 10 to 27, wherein the subject has chronic rhinosinusitis, or wherein the subject has chronic rhinosinusitis and the chronic rhinosinusitis is severe or moderate chronic rhinosinusitis.

29. Use of a composition comprising an anti-TSLP antibody in the manufacture of a medicament for treating chronic rhinosinusitis with nasal polyps in a subject selected to be in need of treatment for chronic rhinosinusitis with nasal polyps, wherein the composition comprising an anti-TSLP antibody is to be administered to the subject in a dose of 210 mg at an interval of every 4 weeks, wherein the antibody comprises

A.

a. a light chain variable domain comprising:

i. a light chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:3;

ii. a light chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:4;

iii. a light chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:5; and

b. a heavy chain variable domain comprising:

i. a heavy chain CDR1 sequence comprising the amino acid sequence set forth in SEQ ID NO:6;

ii. a heavy chain CDR2 sequence comprising the amino acid sequence set forth in SEQ ID NO:7, and

iii. a heavy chain CDR3 sequence comprising the amino acid sequence set forth in SEQ ID NO:8, wherein the antigen binding protein specifically binds to a TSLP polypeptide as set forth in amino acids 29-159 of SEQ ID NO:2; or

B.

wherein the antibody comprises

a. a light chain variable domain selected from the group consisting of:

i. a sequence of amino acids at least 80% identical to SEQ ID NO:12;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:11;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:11; and

b. a heavy chain variable domain selected from the group consisting of:

i. a sequence of amino acids that is at least 80% identical to SEQ ID NO:10;

ii. a sequence of amino acids encoded by a polynucleotide sequence that is at least 80% identical to SEQ ID NO:9;

iii. a sequence of amino acids encoded by a polynucleotide that hybridizes under moderately stringent conditions to the complement of a polynucleotide consisting of SEQ ID NO:9; or c. a light chain variable domain of (a) and a heavy chain variable domain of (b).

30. The use of any one of claims 11 to 29, wherein the light chain variable domain is set out in SEQ ID NO:12 and the heavy chain variable domain is set out in SEQ ID NO:10.

31. The use of claim 30, wherein the antibody is an IgG2 antibody, and has the full length heavy and light chain sequences set out in SEQ ID NOs: 13 and 14, respectively.

32. The use of any one of the preceding claims, wherein the antibody or antibody variant is to be administered for a period of at least 4 months, 6 months, 9 months, 1 year or more.

33. The use of any one of the preceding claims, wherein said anti-TSLP antibody is selected from the group consisting of a monoclonal antibody, a recombinant antibody, an IgG1 antibody, an IgG2 antibody, an IgG3 antibody, and an IgG4 antibody.

34. The use of any one of the preceding claims, wherein the antibody is an IgG2 antibody.

35. The use of any one of the preceding claims, wherein the antibody is a human antibody.

36. The use of any one of the preceding claims wherein the antibody is tezepelumab.

37. Use of an anti-TSLP antibody or antibody variant in the manufacture of a medicament for treating chronic rhinosinusitis in a subject selected to be in need of treatment for chronic rhinosinusitis, wherein the anti-TSLP antibody or antibody variant is to be administered to the subject, wherein the anti-TSLP antibody or antibody variant is described in WO 20220226342A1, WO 20220226339A1, WO2023098491A1, WO2021155634A1, WO2022166072A1, WO2021043221A1, WO2022184074A1, WO2021104053A1, WO2023116925A1, WO2021155861A1, WO2022116858A1, WO2022117079A1, WO2020244544A1, WO2021152488A1, WO2022253147A1, WO2023070948A1, WO2023142309A1, WO2022095689A1, WO2021115240A1, WO2022166739A1 and WO2019100111A1 or set out in Table A.

38. The use of any one of claims 29 to 37, comprising that a pharmaceutical composition comprising the antibody or antibody variant and further comprising a pharmaceutically acceptable carrier or excipient is to be administered to a patient.

39. The use of any one of claims 29 to 38, wherein the administration delays the time to a chronic rhinosinusitis exacerbation compared to a subject not receiving the anti-TSLP antibody or reduces frequency of or levels of co-administered therapy in the subject.

40. The use of claim 39, wherein the co-administered therapy is selected from the group consisting of dupilumab, immunosuppressive or immunomodulating drugs, systemic corticosteroids, cyclosporine, mycophenolate-mofetil, interferon (IFN)-gamma, Janus kinase inhibitors, azathioprine, methotrexate, anti-IL-13 antibodies, anti-IL-5 pathway antibodies, or combinations thereof.

41. The use of claim 40, wherein the administration reduces or eliminates the need for corticosteroid therapy.

42. The use of any one of claims 29 to 41 wherein the subject has a nasal polyp score (NPS) of 0 or 1 after 52 weeks of treatment.

43. The use of any one of claims 29 to 42,

wherein the administration improves one or more measures of chronic rhinosinusitis including Nasal Polyp Score (NSP), Nasal Congestion Score (NCS), loss of smell, SinoNasal Outcome Test 22 Item (SNOT-22), EuroQOL quality of life 5-dimensions 3-level version (EQ-5D-3L), Asthma Control Questionnaire (ACQ-6), Lund-Mackay score, modified Lund-Mackay

Score, incidence of nasal polyp surgery, systemic corticosteroids (SCS) or combinations thereof;

ii) wherein the administration improves one or more symptoms of chronic rhinosinusitis as measured by a patient symptom diary; or

iii) wherein the administration improves one or more symptoms of chronic rhinosinusitis selected from the group consisting of nasal blockage, nasal congestion, runny nose, post-nasal drip, mucus drainage down the throat, prominent nasal obstruction, nasal discharge, loss of smell, asthma symptoms, headache, facial pain, facial pressure, difficulty with sense of smell, difficulty with sleeping due to nasal symptoms, difficulty with daily activities due to nasal symptoms.

44. The use of any one of claims 29 to 43, wherein the chronic rhinosinusitis is severe or moderate chronic rhinosinusitis.

45. The use of any one of the preceding claims, wherein the administration is subcutaneous or intravenous.